EditCo Bio has entered a strategic licensing agreement with Promega, securing access to the latter’s protein-tagging and bioluminescent identification technologies.
Promega's HiBiT, HaloTag, and NanoLuc technologies will be integrated into EditCo's clustered regularly interspaced short palindromic repeats (CRISPR) knock-in services.
This partnership is set to enhance EditCo's engineered cell solution offerings, allowing researchers to create gene-edited models with reproducibility and reliability, which are crucial for a variety of applications.
EditCo noted that the agreement facilitates the company to offer not only genomic knock-ins but also functional validation services.
Its CRISPR knock-ins claim to alter cells into biosensors, which are ideal for protein quantification, the discovery of drugs, and cell-based assays.
This ensures that the engineered cells uphold protein expression, activity, and stability. Such capabilities are vital for researchers needing cell models optimised for quantitative protein analysis.
HiBiT is a bioluminescent peptide tag for protein expression analysis and live cell interaction.
The protein labelling system HaloTag enables covalent bonding of fluorescent and bioluminescent probes for protein interaction studies, and NanoLuc is a luciferase enzyme for real-time monitoring of molecular and cellular processes.
EditCo stated that the agreement is set to support the custom-engineered cell line development using these technologies strictly for research purposes.
Researchers can now utilise these tools to streamline their experimental workflows.
EditCo Bio's chief scientific officer Travis Maures said: “Our collaboration with Promega underscores EditCo’s commitment to delivering industry-leading CRISPR-engineered cells that go beyond genetic modification by incorporating functional validation.
“By integrating HiBiT, HaloTag, and NanoLuc into our knock-in workflows, we provide researchers with powerful tools to track protein expression, interactions, and activity with high sensitivity and accuracy. This partnership will accelerate discoveries in functional genomics, drug development, and therapeutic research.”
